Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Neuropharmacology. 2010 Sep 8;59(7-8):573–581. doi: 10.1016/j.neuropharm.2010.08.017

Fig. 3. Inhibition of hippocampus kindling epileptogenesis in WT and PRKO mice by P.

Fig. 3

P (25 mg/kg, sc) was given twice daily from day 1 to day 14 (dotted line) and animals were stimulated daily (30 min after morning dosing) until they had consistent stage 5 seizures. (A) WT mice treated with P displayed marked retardation of kindling development as expressed by lower mean seizure stage during P treatment and post-drug stimulation sessions. (B) AD duration was similar between control and P groups. (C) PRKO mice treated with P displayed inhibition of kindling development as expressed by lower mean seizure stage during post-drug session. (D) AD duration was similar between control and P groups. Each data point represents the mean of the seizure stage or AD duration of six to eight animals. Small filled squares indicate that the mean value is significantly (p<0.05) different from that in control.